Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins

B. Melkes, L. Hejnova, J. Novotny,

. 2016 ; 389 (12) : 1289-1300. [pub] 20160906

Language English Country Germany

Document type Comparative Study, Journal Article

E-resources Online Full text

NLK ProQuest Central from 2013-01-01 to 1 year ago
Medline Complete (EBSCOhost) from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest) from 2013-01-01 to 1 year ago

There are some indications that biased μ-opioid ligands may diversely affect μ-opioid receptor (MOR) properties. Here, we used confocal fluorescence recovery after photobleaching (FRAP) to study the regulation by different MOR agonists of receptor movement within the plasma membrane of HEK293 cells stably expressing a functional yellow fluorescent protein (YFP)-tagged μ-opioid receptor (MOR-YFP). We found that the lateral mobility of MOR-YFP was increased by (D-Ala(2),N-MePhe(4),Gly(5)-ol)-enkephalin (DAMGO) and to a lesser extent also by morphine but decreased by endomorphin-2. Interestingly, cholesterol depletion strongly enhanced the ability of morphine to elevate receptor mobility but significantly reduced or even eliminated the effect of DAMGO and endomorphin-2, respectively. Moreover, the ability of DAMGO and endomorphin-2 to influence MOR-YFP movement was diminished by pertussis toxin treatment. The results obtained by agonist-stimulated [(35)S]GTPγS binding assays indicated that DAMGO exhibited higher efficacy than morphine and endomorphin-2 did and that the efficacy of DAMGO, contrary to the latter agonists, was enhanced by cholesterol depletion. Overall, our study provides clear evidence that biased MOR agonists diversely affect receptor mobility in plasma membranes as well as MOR/G protein coupling and that the regulatory effect of different ligands depends on the membrane cholesterol content. These findings help to delineate the fundamental properties of MOR regarding their interaction with biased MOR ligands and cognate G proteins.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17013551
003      
CZ-PrNML
005      
20170427103152.0
007      
ta
008      
170413s2016 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00210-016-1293-8 $2 doi
035    __
$a (PubMed)27600870
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Melkes, Barbora $u Department of Physiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
245    10
$a Biased μ-opioid receptor agonists diversely regulate lateral mobility and functional coupling of the receptor to its cognate G proteins / $c B. Melkes, L. Hejnova, J. Novotny,
520    9_
$a There are some indications that biased μ-opioid ligands may diversely affect μ-opioid receptor (MOR) properties. Here, we used confocal fluorescence recovery after photobleaching (FRAP) to study the regulation by different MOR agonists of receptor movement within the plasma membrane of HEK293 cells stably expressing a functional yellow fluorescent protein (YFP)-tagged μ-opioid receptor (MOR-YFP). We found that the lateral mobility of MOR-YFP was increased by (D-Ala(2),N-MePhe(4),Gly(5)-ol)-enkephalin (DAMGO) and to a lesser extent also by morphine but decreased by endomorphin-2. Interestingly, cholesterol depletion strongly enhanced the ability of morphine to elevate receptor mobility but significantly reduced or even eliminated the effect of DAMGO and endomorphin-2, respectively. Moreover, the ability of DAMGO and endomorphin-2 to influence MOR-YFP movement was diminished by pertussis toxin treatment. The results obtained by agonist-stimulated [(35)S]GTPγS binding assays indicated that DAMGO exhibited higher efficacy than morphine and endomorphin-2 did and that the efficacy of DAMGO, contrary to the latter agonists, was enhanced by cholesterol depletion. Overall, our study provides clear evidence that biased MOR agonists diversely affect receptor mobility in plasma membranes as well as MOR/G protein coupling and that the regulatory effect of different ligands depends on the membrane cholesterol content. These findings help to delineate the fundamental properties of MOR regarding their interaction with biased MOR ligands and cognate G proteins.
650    _2
$a bakteriální proteiny $x genetika $x metabolismus $7 D001426
650    _2
$a buněčná membrána $x účinky léků $x metabolismus $7 D002462
650    _2
$a cholesterol $x nedostatek $7 D002784
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a enkefalin, Ala(2)-MePhe(4)-Gly(5)- $x metabolismus $x farmakologie $7 D020875
650    _2
$a FRAP $7 D036681
650    _2
$a proteiny vázající GTP - alfa-podjednotky Gi-Go $x metabolismus $7 D019206
650    _2
$a guanosin 5'-O-(3-thiotrifosfát) $x metabolismus $7 D016244
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a luminescentní proteiny $x genetika $x metabolismus $7 D008164
650    _2
$a konfokální mikroskopie $7 D018613
650    _2
$a morfin $x metabolismus $x farmakologie $7 D009020
650    _2
$a narkotika - antagonisté $x farmakologie $7 D009292
650    _2
$a oligopeptidy $x metabolismus $x farmakologie $7 D009842
650    _2
$a pertusový toxin $x farmakologie $7 D037342
650    _2
$a transport proteinů $7 D021381
650    _2
$a receptory opiátové mu $x agonisté $x genetika $x metabolismus $7 D017450
650    _2
$a rekombinantní fúzní proteiny $x metabolismus $7 D011993
650    _2
$a transfekce $7 D014162
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hejnova, Lucie $u Department of Physiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic.
700    1_
$a Novotny, Jiri $u Department of Physiology, Faculty of Science, Charles University in Prague, Prague, Czech Republic. jiri.novotny@natur.cuni.cz.
773    0_
$w MED00003462 $t Naunyn-Schmiedeberg's archives of pharmacology $x 1432-1912 $g Roč. 389, č. 12 (2016), s. 1289-1300
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27600870 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170427103512 $b ABA008
999    __
$a ok $b bmc $g 1200016 $s 974329
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 389 $c 12 $d 1289-1300 $e 20160906 $i 1432-1912 $m Naunyn-Schmiedeberg's archives of pharmacology $n Naunyn Schmiedebergs Arch Pharmacol $x MED00003462
LZP    __
$a Pubmed-20170413

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...